OVERVIEW OF THE BRAZILIAN OUTCOMES FROM FIRST MULTICENTRIC STUDY WITH USE FROM DATABASE CIBMTR. A PILOT STUDY.

To better understand the outcomes of HSCT in Brazil, we conducted a multicenter study using the CIBMTR database. Seven participating centers extracted their own data through the Data Back to Center tool. Main indications for HSCT-auto were MM(51%), NHL(18%) and HL(17%); Allogeneic, AML(24%), ALL(23%) and SAA(15%). For acute leukemias, risk of death was higher in the 18-40 years group (HR=1.18,p=0.022), 40-60(HR=1.19,p<0.001) and 60+(HR=1.39,p=0.007), compared with 0-18 years, in ALL (HR=1.05,p <0.001, compared with AML) and with partially-matched related donor (HR=1.59,p= 0.003, compared with matched sibling), while URD was not. HSCT in CR2+(HR=1.28,p=0.01) and relapse (HR=2.44,p< 0.001) were risk factors for death. 49%(95CI:44-52)52%(95CI:43-62)45%(95CI:39-51) and 55%(95CI:49-63), somewhat poorer than the CIBMTR: 62 and 70%, respectively.  Limited access to novel drugs for most centers and lack of molecular risk information are possible explanations for these differences. Further studies are necessary to better evaluate our findings and the DBtC tool enables multicenter studies.